{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:46:54Z","timestamp":1771656414810,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10067-017-3867-3","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T02:37:14Z","timestamp":1508121434000},"page":"1123-1127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-fibrotic nintedanib\u2014a new opportunity for systemic sclerosis patients?"],"prefix":"10.1007","volume":"37","author":[{"given":"Ana Catarina","family":"Duarte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jos\u00e9","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"issue":"5","key":"3867_CR1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/1744666X.2017.1263153","volume":"13","author":"C Bruni","year":"2017","unstructured":"Bruni C, Praino E, Allanore Y, Distler O, Gabrielli A, Iannone F et al (2017) Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Rev Clin Immunol 13(5):469\u2013482","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"3867_CR2","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1513\/AnnalsATS.201606-426FR","volume":"13","author":"ER Volkmann","year":"2016","unstructured":"Volkmann ER, Tashkin DP (2016) Treatment of systemic sclerosis-related interstitial lung disease: a review of existing and emerging therapies. Ann Am Thorac Soc 13(11):2045\u20132056","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"3867_CR3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11926-014-0411-1","volume":"16","author":"T Akter","year":"2014","unstructured":"Akter T, Silver RM, Bogatkevich GS (2014) Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease. Curr Rheumatol Rep 16(4):411","journal-title":"Curr Rheumatol Rep"},{"key":"3867_CR4","unstructured":"Bonella F, Stowasser S, Wollin L (2015) Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib [Internet]. Drug Design, Development and Therapy. [cited 2017 Aug 26]. Available from: https:\/\/www.dovepress.com\/idiopathic-pulmonary-fibrosis-current-treatment-options-and-critical-a-peer-reviewed-fulltext-article-DDDT"},{"issue":"5","key":"3867_CR5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2014-207109","volume":"75","author":"J Huang","year":"2017","unstructured":"Huang J, Beyer C, Palumbo-Zerr K, Zhang Y, Ramming A, Distler A et al (2017) Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis 75(5):883\u2013890","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3867_CR6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00281-015-0551-z","volume":"38","author":"O Distler","year":"2016","unstructured":"Distler O, Cozzio A (2016) Systemic sclerosis and localized scleroderma\u2014current concepts and novel targets for therapy. Semin Immunopathol 38(1):87\u201395","journal-title":"Semin Immunopathol"},{"issue":"1","key":"3867_CR7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/14656566.2013.758250","volume":"14","author":"HK Lota","year":"2013","unstructured":"Lota HK, Wells AU (2013) The evolving pharmacotherapy of pulmonary fibrosis. Expert Opin Pharmacother 14(1):79\u201389","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"3867_CR8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1080\/17476348.2016.1249854","volume":"10","author":"J Fukihara","year":"2016","unstructured":"Fukihara J, Kondoh Y (2016) Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis. Expert Rev Respir Med 10(12):1247\u20131254","journal-title":"Expert Rev Respir Med"},{"issue":"3","key":"3867_CR9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10456-017-9543-z","volume":"20","author":"M Ackermann","year":"2017","unstructured":"Ackermann M, Kim YO, Wagner WL, Schuppan D, Valenzuela CD, Mentzer SJ et al (2017) Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis 20(3):359\u2013372","journal-title":"Angiogenesis"},{"issue":"3","key":"3867_CR10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117(3):557\u2013567","journal-title":"J Clin Invest"},{"issue":"25","key":"3867_CR11","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655\u20132666","journal-title":"N Engl J Med"},{"issue":"12","key":"3867_CR12","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NSL et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962\u20133970","journal-title":"Arthritis Rheum"},{"issue":"9","key":"3867_CR13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719","journal-title":"Lancet Respir Med"},{"issue":"10","key":"3867_CR14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.autrev.2011.04.013","volume":"10","author":"S Bosello","year":"2011","unstructured":"Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G et al (2011) B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 10(10):624\u2013630","journal-title":"Autoimmun Rev"},{"issue":"2","key":"3867_CR15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis S-NC, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C et al (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatol Oxf Engl 49(2):271\u2013280","journal-title":"Rheumatol Oxf Engl"},{"issue":"6","key":"3867_CR16","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","volume":"74","author":"S Jordan","year":"2015","unstructured":"Jordan S, Distler JHW, Maurer B, Huscher D, van Laar JM, Allanore Y et al (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74(6):1188\u20131194","journal-title":"Ann Rheum Dis"},{"key":"3867_CR17","doi-asserted-by":"crossref","unstructured":"Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, et al (2015) Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 44(4):428\u201336. 9","DOI":"10.1016\/j.semarthrit.2014.09.002"},{"issue":"10038","key":"3867_CR18","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME et al (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387(10038):2630\u20132640","journal-title":"Lancet"},{"key":"3867_CR19","unstructured":"A study of the efficacy and safety of tocilizumab in participants with systemic sclerosis (SSc)\u2014Full Text View\u2014 ClinicalTrials.gov [Internet]. [cited 2017 Sep 1] Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02453256"},{"issue":"3","key":"3867_CR20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1586\/ers.10.32","volume":"4","author":"A Azuma","year":"2010","unstructured":"Azuma A (2010) Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Expert Rev Respir Med 4(3):301\u2013310","journal-title":"Expert Rev Respir Med"},{"issue":"1\u20133","key":"3867_CR21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","volume":"590","author":"H Oku","year":"2008","unstructured":"Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A et al (2008) Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590(1\u20133):400\u2013408","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"3867_CR22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","volume":"35","author":"H Taniguchi","year":"2010","unstructured":"Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M et al (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35(4):821\u2013829","journal-title":"Eur Respir J"},{"issue":"12","key":"3867_CR23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.2169\/internalmedicine.41.1118","volume":"41","author":"S Nagai","year":"2002","unstructured":"Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T (2002) Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med Tokyo Jpn 41(12):1118\u20131123","journal-title":"Intern Med Tokyo Jpn"},{"issue":"3","key":"3867_CR24","first-page":"235","volume":"31","author":"Y Miura","year":"2014","unstructured":"Miura Y, Saito T, Fujita K, Tanaka T, Tsunoda Y, Azuma A et al (2014) Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 31(3):235\u2013238","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"3867_CR25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4103\/0970-2113.148451","volume":"32","author":"ZF Udwadia","year":"2015","unstructured":"Udwadia ZF, Mullerpattan JB, Balakrishnan C, Richeldi L (2015) Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India Off Organ Indian Chest Soc 32(1):50\u201352","journal-title":"Lung India Off Organ Indian Chest Soc"},{"issue":"27","key":"3867_CR26","doi-asserted-by":"crossref","first-page":"e4113","DOI":"10.1097\/MD.0000000000004113","volume":"95","author":"H Huang","year":"2016","unstructured":"Huang H, Feng RE, Li S, Xu K, Bi YL, ZJ X (2016) A case report: the efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: a CARE-compliant article. Medicine (Baltimore) 95(27):e4113","journal-title":"Medicine (Baltimore)"},{"key":"3867_CR27","doi-asserted-by":"crossref","unstructured":"Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, et al (2016) An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol. jrheum.151322","DOI":"10.3899\/jrheum.151322"},{"issue":"12","key":"3867_CR28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","volume":"365","author":"L Richeldi","year":"2011","unstructured":"Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365(12):1079\u20131087","journal-title":"N Engl J Med"},{"issue":"22","key":"3867_CR29","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071\u20132082","journal-title":"N Engl J Med"},{"key":"3867_CR30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","volume":"113","author":"L Richeldi","year":"2016","unstructured":"Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z et al (2016) Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(\u00ae) trials. Respir Med 113:74\u201379","journal-title":"Respir Med"},{"issue":"5","key":"3867_CR31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.arbres.2016.12.011","volume":"53","author":"A Xaubet","year":"2017","unstructured":"Xaubet A, Molina-Molina M, Acosta O, Bollo E, Castillo D, Fern\u00e1ndez-Fabrellas E et al (2017) Guidelines for the medical treatment of idiopathic pulmonary fibrosis. Arch Bronconeumol 53(5):263\u2013269","journal-title":"Arch Bronconeumol"},{"key":"3867_CR32","unstructured":"Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, et al (2017) Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCISTM). Clin Exp Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3867-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3867-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3867-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T14:25:24Z","timestamp":1570199124000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3867-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,16]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["3867"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3867-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,16]]}}}